Unicycive Therapeutics (UNCY) Net Income towards Common Stockholders (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Net Income towards Common Stockholders came in at -$12.8 million in Q1 2026, down 2614.51% YoY from $510000.0 in Q1 2025, and down 99.01% on a QoQ basis from -$6.4 million in Q4 2025.
Unicycive Therapeutics (UNCY) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$12.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 2614.51% year-over-year to -$12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.7 million (down 43.76% YoY) and the FY2025 annual result came in at -$54.2 million, down 43.23% from the prior year.
- Net Income towards Common Stockholders declined to -$12.8 million in Q1 2026, from -$6.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $3.0 million in Q2 2024 to a low of -$21.5 million in Q4 2024.
- A 5-year average of -$7.3 million and a median of -$5.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 168.52% — and 2026, when it sank 2614.51%.
- Tracing UNCY's Net Income towards Common Stockholders over 5 years: stood at -$5.3 million in 2022, then sank by 46.36% to -$7.8 million in 2023, then slumped by 176.03% to -$21.5 million in 2024, then soared by 70.06% to -$6.4 million in 2025, then sank by 99.01% to -$12.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$12.8 million (Q1 2026), -$6.4 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.72 Mn |
| Mar 31, 2026 | -12.82 Mn |
| Dec 31, 2025 | -6.44 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -6.45 Mn |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | -21.53 Mn |
| Sep 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | -21.17 Mn |
| Dec 31, 2023 | -7.80 Mn |
| Sep 30, 2023 | -4.41 Mn |
| Jun 30, 2023 | -4.44 Mn |
| Mar 31, 2023 | -14.77 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.56 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -5.20 Mn |